The Global Antibiotic Research and Development Partnership (GARDP) said yesterday that an international clinical trial ...

Neonatal sepsis is a leading cause of infant morbidity and mortality in low- and middle-income countries (LMICs), yet despite ...

India has enrolled its first newborn in the global NeoSep1 trial at JIPMER, Puducherry. The study will test antibiotic ...

Each year, sepsis affects more than 30 million people worldwide, causing an estimated six million deaths. Sepsis is the body's extreme response to an infection and is often life-threatening. Since ...

The NeoSep1 trial is expected to enroll 3,000 newborns across Asia and Africa by the end of 2028. ​Along with India, newborns ...

A major multi-country study has found that WHO-recommended first-line antibiotics for neonatal sepsis are likely to be effective in only one-quarter of infections in low- and middle-income countries ...

Hospital patients are at risk of a number of life-threatening complications, especially sepsis—a condition that can kill within hours and contributes to one out of three in-hospital deaths in the U.S.

LISBON, Portugal — A shift toward broader-spectrum antibiotics and increasing antibiotic resistance has led to high levels of mortality and neurodevelopmental impacts in surviving babies, according to ...

Sepsis leads to life-threatening organ failure due to dysregulated host responses to infection and presents uniquely across age groups. Neonatal sepsis, affecting infants in their first 28 days, ...